Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
58 hedge funds and large institutions have $227M invested in Aptose Biosciences, Inc. in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 7 closing their positions.
150% more call options, than puts
Call options by funds: $507K | Put options by funds: $203K
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
14% more funds holding
Funds holding: 51 → 58 (+7)
9% more capital invested
Capital invested by funds: $207M → $227M (+$19.2M)
16% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 19
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$9.31M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$8.41M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$5.61M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.38M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$13.8M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.39M |
| 3 |
Millennium Management
New York
|
-$4.57M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.31M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.77M |
APTO Hedge Fund Activity: Q2 2020 in Review
58 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q2 2020, worth a combined $227M — up 9.2% from $207M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new APTO positions and 7 closed out — a net gain of 7 holders — while 16 added to existing stakes and 19 trimmed.
The largest buyer was Pictet Asset Management (UK), adding an estimated $9.31M. The largest seller was Polar Capital, cutting an estimated $13.8M.
- 58 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q2 2020, up from 51 in Q1 2020.
- Funds reported $227M of Aptose Biosciences, Inc. stock for Q2 2020, up 9.2% quarter-over-quarter.
- 14 funds opened new Aptose Biosciences, Inc. positions in Q2 2020 and 7 closed out, a net change of +7 holders.
- The largest Aptose Biosciences, Inc. buyer in Q2 2020 was Pictet Asset Management (UK), an estimated $9.31M added.
- The largest Aptose Biosciences, Inc. seller in Q2 2020 was Polar Capital, an estimated $13.8M sold.
Based on aggregated 13F filings for Q2 2020.